3 terminated. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 3 | 2 | Terminated 2 |
Follow COVID 19: new trials by email Literature Review of COVID 19 trials Research Report on COVID 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled Ciclesonide for Outpatients With COVID19 Normal Saline intranasal and placebo inhaler, Ciclesonide, Ciclesonide nasal - COVID 19 | Phase 2 / Phase 3 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 215 | 2020-09-15 | 2022-06-10 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| Trial of Hydroxychloroquine In Covid-19 Kinetics Hydroxychloroquine, Placebo - Covid 19, Corona Virus Infection | Phase 2 / Phase 3 | Terminated | University of South Alabama | 3 | 2020-04-17 | 2022-01-03 |
COVID-19 (3) · Coronavirus Infections (2) · Cardiovascular Diseases (1) · Cytokine Release Syndrome (1) · Dyspnea (1) · Heart Failure (1) · Myocardial Infarction (1) · Pneumonia (1) · Pulmonary Edema (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Coronaviridae Infections (3) · Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia, Viral (3) · RNA Virus Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Virus Diseases (3) · Pneumonia (2) · Coronavirus Infections (1) · Heart Diseases (1) · Infarction (1) · Inflammation (1) · Ischemia (1)
Hydroxychloroquine (1) · VIP-ELP fusion molecule PB1046 (1) · ciclesonide (1)
McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · PhaseBio Pharmaceuticals Inc. (1) · University of South Alabama (1)
United States (2) · Canada (1)